Validation of the albumin-bilirubin score for identifying decompensation risk in patients with compensated cirrhosis

Table 1 Baseline characteristics of patients with compensated cirrhosis, n (%)

Variable	n = 123
Age, yr, mean (SD)	63.9 (12.3)
Male	72 (58.5)
Body mass index, kg/m2, mean (SD)	24.5 (3.7)
Obesity	54 (43.9)
Diabetes	33 (26.8)
Etiology of disease
HBV	43 (35)
HCV	30 (24.4)
NASH	29 (23.6)
Alcohol	19 (15.4)
Autoimmune hepatitis	2 (1.6)
Laboratory data
Creatinine, mg/dL, median (IQR)	0.8 (0.7-0.9)
Albumin, g/dL, median (IQR)	4 (3.4-4.3)
Bilirubin, mg/dL, median (IQR)	0.9 (0.6-1.5)
AST, U/L, median (IQR)	44 (28-66)
ALT, U/L, median (IQR)	33 (24-58)
Platelets, × 109/L, median (IQR)	142 (104-200)
INR, median (IQR)	1.1 (1-1.2)
Child-Pugh grade
A	113 (91.9)
B	10 (8.1)
Decompensation event	17 (13.8)
Variceal bleeding	8 (47)
Ascites development	5 (29.4)
Grade 3 or 4 hepatic encephalopathy	4 (23.6)
MELD, median (IQR)	8.7 (7.8-10.1)
ALBI score, median (IQR)	-2.63 (-2.91 to -2.06)
ALBI grade
1	64 (52)
2	53 (43.1)
3	6 (4.9)
ALBI-FIB4 score, median (IQR)	-2.79 (-3.28 to -1.93)
FIB-4 score, median (IQR)	3.2 (1.8-5.3)

NASH: Nonalcoholic steatohepatitis; HBV: Hepatitis B virus; HCV: Hepatitis C virus; AST: Aspartate transaminase; ALT: Alanine transaminase; INR: International normalized ratio; MELD: Model for end-stage liver disease; ALBI: Albumin-bilirubin; FIB-4: Fibrosis-4; SD: Standard deviation; IQR: Interquartile range